Graf Acquisition Corp. IV Completes Business Combination with NKGen Biotech

Graphite Bio Completes Merger with LENZ Therapeutics; Combined Company to Trade as LENZ

March 21, 2024

Biotechnology

LENZ Therapeutics completed its previously announced merger with Graphite Bio and will commence trading on Nasdaq under the ticker LENZ. The transaction included a 1-for-7 reverse stock split, a special cash dividend, and a concurrent $53.5 million PIPE from a syndicate of healthcare investors, leaving the combined company with approximately $210 million in cash to support late-stage CLARITY Phase 3 readouts and planned NDA submission in mid-2024.

Bruker Corporation Acquires NanoString Technologies Business

May 6, 2024

Medical Devices

Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.

Ignyte Acquisition Corp. Completes Business Combination with Peak Bio Co., Ltd.; Peak Bio to List on NASDAQ

November 2, 2022

Biotechnology

Ignyte Acquisition Corp. completed a business combination with Peak Bio Co., Ltd., resulting in the combined company operating as Peak Bio, Inc. and commencing trading on NASDAQ under the ticker symbols PKBO (common stock) and PKBOW (warrants). The transaction positions Peak Bio to access public markets and raise capital to advance its oncology and inflammatory disease therapeutics, with Hoyoung Huh as Chairman and Stephen LaMond as COO.

Global Cord Blood Corporation Acquires Cellenkos, Inc.

April 29, 2022

Biotechnology

Global Cord Blood Corporation (GCBC) agreed to acquire 100% of clinical-stage biotech Cellenkos, Inc., and worldwide rights to most of its products (excluding those under an Incyte collaboration). The transaction consideration includes approximately 125 million new shares (as-converted) valued at $11 per share plus $664 million in cash; GCBC said the acquisition expands its capabilities into allogeneic T-reg cell therapies and supports global commercialization and R&D.

Novacyt Acquires Yourgene Health plc

September 8, 2023

Medical Devices

Novacyt, through its wholly-owned subsidiary Novacyt UK Holdings Limited, has completed the acquisition of Yourgene Health plc by way of a court-sanctioned scheme of arrangement. The deal brings together Novacyt's diagnostics capabilities with Yourgene's genomic technologies and services to create a larger, diversified international molecular diagnostics business headquartered in Manchester, UK.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.